A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.

Trial Details

NCT ID

NCT04486352

Phase

PHASE1 / PHASE2

Sponsor

Alliance Foundation Trials, LLC.

Status

RECRUITING

Cancer Type

Uterine Cancer

Interventions

Atezolizumab - 28 Day Cycle
Bevacizumab
Ipatasertib
Talazoparib
Trastuzumab emtansine
Tiragolumab

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
San Francisco, California, United States|37.77493,-122.41942
Washington D.C., District of Columbia, United States|38.89511,-77.03637
Miami Beach, Florida, United States|25.79065,-80.13005
Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

Recurrent or persistent endometrial carcinoma which has progressed or recurred after at least 1, but no more than 2, prior lines of therapy. Prior …
Measurable disease per RECIST 1.1
Availability of a representative tumor specimen that is suitable for determination of biomarker status via central testing (F1CDx) OR If a patient …
Life expectancy \> 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →